SAN DIEGO, Feb. 7, 2012 /PRNewswire/ -- ADVENTRX Pharmaceuticals, Inc. (NYSE Amex: ANX) today announced that the Company's Chief Executive Officer, Brian M. Culley, will present at the 14th Annual BIO CEO & Investor Conference on Tuesday, February 14, 2012 at 11:00 a.m. Eastern time, in the Park South Salon at the Waldorf=Astoria Hotel in New York.
Interested parties can access a live audio webcast and slide presentation on the ADVENTRX Pharmaceuticals web site at http://www.adventrx.com/. An archived presentation will be available on the web site for 30 days.
About ADVENTRX Pharmaceuticals
ADVENTRX Pharmaceuticals is a biopharmaceutical company focused on developing proprietary product candidates. The Company's lead product candidate is ANX-188, a rheologic, antithrombotic and cytoprotective agent that improves micro-vascular blood flow, which has potential application in treating a wide range of diseases and conditions, such as complications arising from sickle cell disease. The Company also is developing ANX-514, a novel, detergent-free formulation of the chemotherapy drug docetaxel. More information can be found on the Company's web site at http://www.adventrx.com/.
SOURCE ADVENTRX Pharmaceuticals, Inc.
Ioana C. Hone of ADVENTRX Pharmaceuticals, +1-858-552-0866 Ext. 303, ir@adventrx.com
